Safety and preliminary evidence of biologic efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer

Venkataswarup Tiriveedhi, Natalia Tucker, John Herndon, Jin Li, Mark Sturmoski, Matthew Ellis, Cynthia Ma, Michael Naughton, Albert Lockhart, Feng Gao, Timothy Fleming, Peter Goedegebuure, Thalachallour Mohanakumar, William E. Gillanders

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Purpose: Mammaglobin-A (MAM-A) is overexpressed in 40% to 80% of primary breast cancers. We initiated a phase I clinical trial of a MAM-A DNA vaccine to evaluate its safety and biologic efficacy. Experimental Design: Patients with breast cancer with stable metastatic disease were eligible for enrollment. Safety was monitored with clinical and laboratory assessments. The CD8 T-cell response was measured by ELISPOT, flow cytometry, and cytotoxicity assays. Progression-free survival (PFS) was described using the Kaplan-Meier product limit estimator. Results: Fourteen subjects have been treated with the MAM-A DNA vaccine and no significant adverse events have been observed. Eight of 14 subjects were HLA-A2+, and the CD8 T-cell response to vaccination was studied in detail. Flow cytometry demonstrated a significant increase in the frequency of MAM-A- specific CD8 T cells after vaccination (0.9% ± 0.5% vs. 3.8% ± 1.2%; P < 0.001), and ELISPOT analysis demonstrated an increase in the number of MAM-A-specific IFNγ -secreting T cells (41 ± 32 vs. 215 ± 67 spm; P < 0.001). Although this study was not powered to evaluate progression-free survival (PFS), preliminary evidence suggests that subjects treated with the MAM-A DNA vaccine had improved PFS compared with subjects who met all eligibility criteria, were enrolled in the trial, but were not vaccinated because of HLA phenotype. Conclusion: The MAM-A DNA vaccine is safe, capable of eliciting MAM-A-specific CD8 T-cell responses, and preliminary evidence suggests improved PFS. Additional studies are required to define the potential of the MAM-A DNA vaccine for breast cancer prevention and/or therapy.

Original languageEnglish (US)
Pages (from-to)5964-5975
Number of pages12
JournalClinical Cancer Research
Volume20
Issue number23
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tiriveedhi, V., Tucker, N., Herndon, J., Li, J., Sturmoski, M., Ellis, M., Ma, C., Naughton, M., Lockhart, A., Gao, F., Fleming, T., Goedegebuure, P., Mohanakumar, T., & Gillanders, W. E. (2014). Safety and preliminary evidence of biologic efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer. Clinical Cancer Research, 20(23), 5964-5975. https://doi.org/10.1158/1078-0432.CCR-14-0059